Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Drammen – page 49

616 clinical trials in Drammen, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Drammen at a glance
616
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

616 trials in Drammen

Open in trial search

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma+2

Not recruiting

Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Oslo University Hospital HF

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Nivolumab, Ipilimumab, and UV1 Vaccine for Patients with Malignant Pleural Mesothelioma After Initial Chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Oslo University Hospital HF

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Study on Physical Activity and Joint Health in Patients Aged 12 and Older with Severe Hemophilia A Treated with Efanesoctocog Alfa for 24 Months

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide
  • Sponsor:Kartos Therapeutics Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Drammen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer types, including pancreatic ductal cancer, small-cell lung cancer, and advanced melanoma. Studies evaluate new combination therapies and treatment approaches.

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Colon Cancer Treatment

Research emphasizes improving survival rates and treatment efficacy through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments. Trials explore new approaches for stroke prevention and management of heart conditions.

  • Atrial Fibrillation Management
  • Stroke Prevention
  • Atherosclerotic Disease

Focus on developing innovative antiplatelet therapies and investigating cardiovascular safety in various patient populations.

03 Chronic Disease Management

Studies addressing chronic conditions including Multiple Sclerosis, Crohn's Disease, and Rheumatoid Arthritis. Trials evaluate new therapeutic approaches and drug combinations.

  • COPD Treatment
  • Inflammatory Conditions
  • Metabolic Disorders

Research aims to improve disease control and patient outcomes through innovative treatment strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.